Comparison WAC of Remicade vs biosimilars in the U.S. as of Q3 2020
As of Q3 2020, the wholesale acquisition cost of autoimmune disease drug Remicade was around 1,168 U.S. dollars, compared to 946 U.S. dollars for the biosimilar Inflectra. Biosmilars of Remicade were able to reduce costs between 19 and 59 percent. This statistic illustrates a comparison WAC of Remicade vs biosimilars in the United States.